ClinicalTrials.gg
CompletedNCT04577885Updated Oct 8, 2020

A Rifampin Effect Study of SHR2554 on Healthy Chinese Adult Subjects

A Phase 1 interventional study of SHR2554 and Rifampin in Healthy, sponsored by Jiangsu HengRui Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-10-08.

Sponsored by Jiangsu HengRui Medicine Co., Ltd. · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled May 2020, registered Sep 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objective of the study is to evaluate the effect of Rifampin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR2554 tablets. The secondary objective of the study is to evaluate the safety of single-dose oral administration of SHR2554 in healthy subjects.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd. is the lead sponsor of 573 studies on the registry; 88 are open to participants now.

Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The is signed before the trial, and the content, process and possible adverse reactions are fully understood;
  2. Be able to complete the study according to the requirements of the test scheme;
  3. Healthy male and female subjects aged 18 to 45 years (including both ends) on the date of signing informed consent;
  4. The body weight of male subjects is no less than 50 kg and that of female subjects is no less than 45 kg. (BMI) is in the range of 19.0-26.0 kg/m2 (including the critical value).

Exclusion criteria

Exclusion Criteria:

  1. Participated in blood donation within 3 months before taking the study drug and donate blood ≥400 mL, or received blood transfusion;
  2. Allergic constitution, including severe drug allergy or drug allergy history; allergic history of SHR2554 tablets, Rifampin, Rifamycin or their ;
  3. People who have a history of drug and/or alcohol abuse, have a positive alcohol or drug screening test, or have a history of drug abuse in the past five years or have used drugs within 3 months before the test;
  4. Smoking and alcohol addicts (drinking 14 units of alcohol per week: 1 unit = 285 ml beer, 25 ml spirits, or 100 ml wine; smoking ≥ 5 cigarettes a day) and unable to prohibit smoking and alcohol during the test period;
  5. Comprehensive physical examination (vital signs, physical examination), routine laboratory examinations (blood routine, blood biochemistry, urine routine, etc.), 12-lead , chest X-ray, heart color Doppler ultrasound, etc. are abnormal and have clinical significance as judged by the investigator;
  6. Echocardiography suggests that the (LVEF) is less than 50% or the (QTcF) corrected by Fridericia method in 12-lead ECG is ≥ 470msec;
  7. A clear medical history of primary diseases of important organs such as nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolism and musculoskeletal system, etc., the investigator considers not suitable for participating in this study;
  8. Those who have undergone any surgery within 6 months before screening;
  9. Hepatotoxic drugs (such as Dapsone, Erythromycin, Fluconazole, Ketoconazole, Rifampin) have been taken for a long period of time (over 7 consecutive days) in the 6 months before screening;
  10. Those who have taken any clinical trial drugs within 3 months;
  11. Any drug that changes liver enzyme activity was taken within 28 days before taking the study drug;
  12. Any prescription or over-the-counter drugs taken within 14 days before taking the study drug;
  13. Ingested any vitamin products, health products or Chinese herbal medicine within 14 days before taking the study drug;
  14. antibody positive, antibody positive, positive, syphilis antibody positive;
  15. Ingested grapefruit or products containing grapefruit, food or drink containing caffeine, xanthine or alcohol within 48 hours before taking the study drug; strenuous exercise, or other factors that affect the absorption, distribution, metabolism, and excretion of the study drug;
  16. The subjects have a childbearing plan and are unwilling to take effective measures 2 weeks before the study administration (only female subjects) and 3 months after the last administration of the drug; those who are fertile and whose serum hCG test is not negative before the study medication;
  17. People with a history of fainting needles and blood, have difficulty in blood collection or cannot tolerate venipuncture blood collection;
  18. Women during pregnancy and lactation;
  19. Subjects with other factors not suitable to participate in this study as considered by the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    experimental group

    Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules

    Drug: SHR2554 and Rifampin

Interventions

  • DrugSHR2554 and Rifampin

    Drug pages: Zeprumetostat · Rifampin

    Single-dose oral administration of SHR2554 and multiple-dose oral administration of Rifampin Capsules

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics parameter: Cmax of SHR2554

    Peak Plasma Concentration (Cmax) of SHR2554

    Time frame: from Day 1 to Day 13

  2. Pharmacokinetics parameter: AUC of SHR2554

    Area under the plasma concentration versus time curve (AUC) of SHR2554

    Time frame: from Day 1 to Day 13

Secondary outcomes

  1. Other pharmacokinetics parameter: Tmax of SHR2554

    Time to maximum plasma concentration (Tmax) of SHR2554

    Time frame: from Day 1 to Day 13

  2. Other pharmacokinetics parameter: T1/2 of SHR2554

    Half-life of elimination (T1/2) of SHR2554

    Time frame: from Day 1 to Day 13

  3. The incidence and severity of adverse events/serious adverse events

    Based on NCI-CTC AE 5.0

    Time frame: from Day 1 to Day 13

07

Study locations

1 site
  • Jiangsu HengRui Medicine Co., Ltd.
    Shanghai, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Aug 2020, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2020
First posted
Oct 8, 2020
StartActual
May 28, 2020
Primary completionActual
Aug 30, 2020
CompletionActual
Sep 20, 2020
Last update
Oct 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04577885
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
May 28, 2020
Primary completion
Aug 30, 2020
Completion
Sep 20, 2020
Last update
Oct 8, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zeprumetostat · Rifampin

Start the discussion